Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales were $10.4 billion in the quarter, up 20%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
2Q Revenues: $20.8 billion (+11%)
2Q Earnings: $4.0 billion (+3%)
YTD Revenues: $40.8 billion (+12%)
YTD Earnings: $8.3 billion (+1%)
Comments: Worldwide Pharmaceutical sales were $10.4 billion in the quarter, up 20%. Domestic sales increased 18% and international sales increased 23%. Sales included the impact of Actelion Ltd. which contributed 6.6%, to worldwide operational sales growth. Growth was driven by Stelara, up 36% to $1.3 billion; Zytiga up 63% to $909 million; Darzalex, up 71% to $511 million; Imbruvica, up 38% to $620 million; Simponi/Simponi Aria, up 25% to $548 million; Invega Sustenna, up 15% to $720 million; and Xarelto up 6% to $679 million. Remicade sales were down 14% to $1.3 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters